Elysium Therapeutics Revenue and Competitors

Our Mission Elysium’s mission is to disrupt the $10B+ prescription opioid pain medications market by accomplishing what others thought impossible – to create a new class of opioid pain relievers that protect individuals from oral misuse, abuse, and fatal overdose (that is, from the simultaneous ingestion of multiple pills). Elysium’s technologies are designed to (i) prevent fatal overdoses, saving thousands of lives each year; (ii) preclude the primary route of misuse and abuse of prescription opioids, and disrupt heartbreaking and often lethal progression to fentanyl and heroin use and addiction; and (iii) provide safe, highly-effective pain relief to patients. Our Vision - Elysium’s technologies will set a new standard of safety for prescription opioids - Like the auto industry, pharmaceutical companies will soon be required to meet minimum safety standards for their prescription opioid products, whether branded or generic, by a certain date. Such safety standards will be raised over time as new technologies are developed. - All “unprotected” opioids will be removed from the market by the FDA to for safety reasons in order to maximize the beneficial impact of abuse-deterrent, overdose-protected alternatives. Our Strategy Our new therapeutic entity strategy offers: - Highly effective pain-relief - A high probability of success - First- and best-in-class labeling that competitors’ technologies are incapable of offering - Strong key stakeholder interest - Potential for rapid commercialization with FDA Breakthrough Therapy Designation Our Technologies Experts say that the best way to defeat an epidemic is to reduce exposure. In this case, the challenge is to reduce exposure without compromising patient care. Our technologies are designed to control exposure without disrupting patient care: - O2P™: Protects against the primary route of abuse, oral overdose - XpiRx™: Unprecedented diversion-resistance to reduce the supply of abused opioids